Christophe Arbet-engels - Net Worth and Insider Trading

Christophe Arbet-engels Net Worth

The estimated net worth of Christophe Arbet-engels is at least $1,531 dollars as of 2025-05-28. Christophe Arbet-engels is the Chief Medical Officer of X4 Pharmaceuticals Inc and owns about 474 shares of X4 Pharmaceuticals Inc (XFOR) stock worth over $1,531. Details can be seen in Christophe Arbet-engels's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christophe Arbet-engels has not made any transactions after 2025-01-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Christophe Arbet-engels

Christophe Arbet-engels Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christophe Arbet-engels owns 3 companies in total, including Millendo Therapeutics Inc (MLND) , Tempest Therapeutics Inc (TPST) , and X4 Pharmaceuticals Inc (XFOR) .

Click here to see the complete history of Christophe Arbet-engels’s form 4 insider trades.

Insider Ownership Summary of Christophe Arbet-engels

Ticker	Company	Transaction Date	Type of Owner
MLND	Millendo Therapeutics Inc	2020-05-25	Chief Medical Officer
TPST	Tempest Therapeutics Inc	2020-02-10	Chief Medical Officer
XFOR	X4 Pharmaceuticals Inc	2025-01-24	Chief Medical Officer

Christophe Arbet-engels Latest Holdings Summary

Christophe Arbet-engels currently owns a total of 1 stock. Christophe Arbet-engels owns 474 shares of X4 Pharmaceuticals Inc (XFOR) as of January 24, 2025, with a value of $1,531.

Latest Holdings of Christophe Arbet-engels

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XFOR	X4 Pharmaceuticals Inc	2025-01-24	474	3.23	1,531

Holding Weightings of Christophe Arbet-engels

Christophe Arbet-engels Form 4 Trading Tracker

According to the SEC Form 4 filings, Christophe Arbet-engels has made a total of 1 transactions in X4 Pharmaceuticals Inc (XFOR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in X4 Pharmaceuticals Inc is the sale of 387 shares on January 24, 2025, which brought Christophe Arbet-engels around $5,231.

Insider Trading History of Christophe Arbet-engels

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christophe Arbet-engels Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Christophe Arbet-engels Ownership Network

Ownership Network List of Christophe Arbet-engels

No Data

Ownership Network Relation of Christophe Arbet-engels

Christophe Arbet-engels Owned Company Details

What does Millendo Therapeutics Inc do?

Who are the key executives at Millendo Therapeutics Inc?

Christophe Arbet-engels is the Chief Medical Officer of Millendo Therapeutics Inc. Other key executives at Millendo Therapeutics Inc include Chief Development Officer Ryan Zeidan , director & President and CEO Julia C. Owens , and General Counsel and Secretary Tamara L Joseph .

Millendo Therapeutics Inc (MLND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Millendo Therapeutics Inc (MLND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Millendo Therapeutics Inc (MLND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Millendo Therapeutics Inc (MLND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Millendo Therapeutics Inc Insider Transactions

No Available Data

What does Tempest Therapeutics Inc do?

Who are the key executives at Tempest Therapeutics Inc?

Christophe Arbet-engels is the Chief Medical Officer of Tempest Therapeutics Inc. Other key executives at Tempest Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , director & Chief Executive Officer Stephen R Brady , and Chief Medical Officer Samuel Whiting .

Tempest Therapeutics Inc (TPST) Insider Trades Summary

Over the past 18 months, Christophe Arbet-engels made no insider transaction in Tempest Therapeutics Inc (TPST). Other recent insider transactions involving Tempest Therapeutics Inc (TPST) include a net sale of 787,999 shares made by Versant Venture Capital Vi, L.p. , a net purchase of 35,000 shares made by Stephen R Brady , and a net purchase of 4,672 shares made by Samuel Whiting .

In summary, during the past 3 months, insiders sold 0 shares of Tempest Therapeutics Inc (TPST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 60,615 shares of Tempest Therapeutics Inc (TPST) were sold and 3,052 shares were bought by its insiders, resulting in a net sale of 57,564 shares.

Tempest Therapeutics Inc (TPST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tempest Therapeutics Inc Insider Transactions

No Available Data

What does X4 Pharmaceuticals Inc do?

Who are the key executives at X4 Pharmaceuticals Inc?

Christophe Arbet-engels is the Chief Medical Officer of X4 Pharmaceuticals Inc. Other key executives at X4 Pharmaceuticals Inc include Chief Commercial Officer Mark Baldry , Chief Operating Officer Mary Dibiase , and See Remarks Adam S. Mostafa .

X4 Pharmaceuticals Inc (XFOR) Insider Trades Summary

Over the past 18 months, Christophe Arbet-engels made 1 insider transaction in X4 Pharmaceuticals Inc (XFOR) with a net sale of 11,624. Other recent insider transactions involving X4 Pharmaceuticals Inc (XFOR) include a net sale of 451,076 shares made by Paula Ragan , a net sale of 111,687 shares made by Mary Dibiase , and a net sale of 385,639 shares made by Adam S. Mostafa .

In summary, during the past 3 months, insiders sold 0 shares of X4 Pharmaceuticals Inc (XFOR) in total and bought 1,032 shares, with a net purchase of 1,032 shares. During the past 18 months, 36,408 shares of X4 Pharmaceuticals Inc (XFOR) were sold and 2,200 shares were bought by its insiders, resulting in a net sale of 34,208 shares.

X4 Pharmaceuticals Inc (XFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

X4 Pharmaceuticals Inc Insider Transactions

No Available Data

Christophe Arbet-engels Mailing Address

Above is the net worth, insider trading, and ownership report for Christophe Arbet-engels. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Christophe Arbet-engels's mailing address is: Ann Arbor Mi 48104.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.